Table 2.
Respondents impressions of the 2017 Canadian opioid guideline.
| Awareness of the guideline (n = 686), n (%) | |
| Yes | 630 (92%) |
| No | 56 (8%) |
|
| |
| Guideline version read (n = 588), n (%) | |
| Print version only | 229 (39%) |
| Online MAGICapp version only | 250 (43%) |
| Print and online MAGICapp versions | 109 (18%) |
| Neither | |
|
| |
| Format of the print version (n = 326), n (%) | |
| Excellent | 29 (9%) |
| Good | 239 (73%) |
| Unsure/do not recall | 31 (10%) |
| Poor | 24 (7%) |
| Very poor | 3 (1%) |
|
| |
| Format of the online MAGICapp version (n = 345), n (%) | |
| Excellent | 63 (18%) |
| Good | 219 (64%) |
| Unsure/do not recall | 38 (11%) |
| Poor | 23 (7%) |
| Very poor | 2 (1%) |
|
| |
| Advantages over competing opioid guidelines (n = 195), n (%)1 | |
| National in scope | 114 (59%) |
| More specific guidance | 103 (53%) |
| Broadly endorsed | 94 (48%) |
| Better evidence review process | 83 (43%) |
|
| |
| The 2017 guideline is evidence-based (n = 505), n (%) | |
| Strongly agree | 65 (13%) |
| Agree | 240 (48%) |
| Uncertain | 160 (32%) |
| Disagree | 36 (7%) |
| Strongly disagree | 4 (1%) |
1Percentages add up to >100% as respondents could endorse more than one option.